[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nonfluent-variant-primary-progressive-aphasia-nfvppa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nonfluent-variant-primary-progressive-aphasia-nfvppa":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100595517","phase-2-clinical-study-of-neflamapimod-in-patients-with-primary-progressive-aphasia-100595517",false,"NCT07033481","Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia","A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)","Inclusion Criteria:\n\n* Men and women aged 40-85 years at Screening.\n* Participant or participant's legally authorized representative (where applicable) is willing and able to provide written informed consent.\n* Clinical diagnosis of nfvPPA by consensus criteria \\[Gorno-Tempini et al, 2011\\].\n\n  * At least one of the following core features must be present:\n\n    1. Agrammatism in language production\n    2. Effortful, halting speech with inconsistent speech sound errors and distortions (apraxia of speech)\n  * At least 2 of 3 of the following other features must be present:\n\n    1. Impaired comprehension of syntactically complex sentences\n    2. Spared single-word comprehension\n    3. Spared object knowledge\n* Global CDR® plus National Alzheimer's Coordinating Center Frontotemporal Lobar Degeneration (NACC FTLD) score of 0.5 or 1 during Screening.\n* CDR® plus NACC FTLD language domain score of 0.5, 1 or 2 during Screening.\n* Normal or corrected eyesight and auditory abilities, sufficient to perform all aspects of the study scales and assessments.\n* Fluent in English, per Investigator judgement.\n* Must have reliable study partner that is able to attend all study visits with participant. Study partner must be able to read, write, and understand the English language.\n\nExclusion Criteria:\n\n* Brain Magnetic Resonance Image (MRI) incompatible with a diagnosis of nfvPPA.\n* History or evidence of a central nervous system (CNS) condition other than nfvPPA which may cause symptoms of aphasia or dementia, including but not limited to Alzheimer's disease (AD), Dementia with Lewy Bodies (DLB), inflammatory\u002Fdemyelinating CNS conditions, Creutzfeldt Jakob disease, vascular dementia, post-stroke dementia, etc.\n* Features or Parkinsonism, corticobasal syndrome or progressive supranuclear palsy that are as or more prominent than the language features of nfvPPA, and\u002For motor features which are sufficiently severe that they could significantly impact performance on any of the clinical or neuropsychological measures.\n* Plasma pTau217 result with a high likelihood of the presence of amyloid pathology at Screening or documented evidence of positive biomarkers associated with Alzheimer's disease pathology (e.g., abnormal plasma Aβ42\u002F40 ratio, abnormal CSF phospo-tau\u002Famyloid ratio, or presence of amyloid tracer update on brain amyloid positron emission tomography \\[PET\\] imaging).\n* Known progranulin (GRN) mutations.\n* Ongoing major and active psychiatric disorder and\u002For other concurrent medical condition that, in the opinion of the Investigator, might compromise safety and\u002For compliance with study requirements.\n* Metabolic or toxic encephalopathy or dementia due to a general medical condition.\n* History of previous neurosurgery to the brain within the past five years.\n* Suicidality, defined as active suicidal thoughts within 6 months before Screening or at Baseline, defined as answering yes to items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS), or history of suicide attempt in previous 2 years, or, in the Investigator's opinion, at serious risk of suicide.\n* Clinically relevant intellectual impairment that may interfere with the ability to complete the study scales and assessments, at the discretion of the Investigator.\n* Diagnosis of alcohol or drug abuse within the previous 2 years.\n* Poorly controlled clinically significant medical illness, such as hypertension; myocardial infarction within 6 months; uncompensated congestive heart failure or other significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic\u002Fendocrine disorders or other disease that would interfere with assessment of drug safety.\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>2 × the upper limit of normal (ULN), total bilirubin \\>1.5 × ULN, and\u002For International Normalized Ratio (INR) \\>1.5.\n\n  * If participant has a documented history of Gilbert's syndrome, criterion of total bilirubin \\>1.5 x ULN is not applicable.\n  * If participant is taking anticoagulants (e.g., warfarin), and has no known liver issues, INR \\>3.\n* Known human immunodeficiency virus, hepatitis B, or active hepatitis C virus infection.\n* Participated in a study of an investigational drug or transcranial direct current stimulation less than 6 weeks or 5 half-lives of an investigational drug, whichever is longer, before enrollment in this study.\n* Male with female partner(s) of childbearing potential, unwilling or unable to adhere to contraception requirements specified in the protocol.\n* Female of childbearing potential (see Section 5.10), with a positive pregnancy test result during Screening and are unwilling or unable to adhere to contraception requirements specified in the protocol.\n* Weight less than 50 kg at Screening.\n\nThe following additional exclusion criteria applies for participants undergoing (18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography) 18F-FDG PET-CT (18F-FDG PET-CT scans are optional):\n\n* Blood glucose levels \\>200 mg\u002FdL.\n* Contraindications to having a PET scan.","ALL","40 Years","85 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.",[27],"Nonfluent Variant Primary Progressive Aphasia (nfvPPA)",[29,30,31,32,33,34,35,36,37,38,39],"Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Neurocognitive Disorders","Mental Disorders","Neurodegenerative Diseases","Aphasia","Language Disorder","Frontotemporal Dementia","Speech and Language Disorder","Primary Progressive Aphasia","RECRUITING","2026-04-20",{"date":43,"type":44},"2026-04-22","ACTUAL",{"date":46,"type":44},"2025-10-02",{"date":48,"type":21},"2026-10",{"name":50,"class":51},"EIP Pharma Inc","INDUSTRY",7,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":78,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":106},"100609830","intervention-for-communication-quality-of-life-in-primary-progressive-aphasia-100609830","NCT07219680","Intervention for Communication Quality of Life in Primary Progressive Aphasia","Intervention to Promote Communication Quality of Life for Persons With Language-Led Dementia and Their Partners: A Randomized Pilot Trial","Multi-PA","Inclusion Criteria for Persons with PPA:\n\n* A PPA (Gorno-Tempini et al., 2011) or \"PPA-plus\" (Mesulam et al., 2001) diagnosis\n* MMSE score of 15 or higher and must be able to produce single monosyllabic words intelligibly\n* Must speak English, Spanish or both languages (i.e., bilingual speakers of English or Spanish)\n* Hearing and vision adequate for participation in teleconference meetings\n* Must have a study partner available (someone who will commit to attending teleconference sessions, as needed, during assessment and treatment phases)\n\nInclusion criteria for Care Partners:\n\n* Partners must express willingness to attend and participate in assessment and treatment sessions, including those targeting dyadic communication goals\n* Partners must speak English, Spanish or both languages (i.e., bilingual speakers of English or Spanish)\n* Partner's hearing and vision should be adequate for participation in teleconference meetings\n\nThe participant and\u002For study partner must have basic experience using a computer.\n\nExclusion criteria for persons with PPA:\n\n* Other central nervous system or medical diagnosis that can account for symptoms\n* Psychiatric diagnosis that can account for symptoms",{"count":62,"type":21},30,[64],"NA","The goal of this clinical trial is to learn whether a personalized, multi-component, virtual speech language treatment program can improve communication and quality of life for adults with primary progressive aphasia (PPA) and their primary communication partners. The study will enroll participants who speak English and\u002For Spanish.\n\nThe main questions the study aims to answer are:\n\n* Is the telerehabilitation program feasible and acceptable for people with PPA and their study partners?\n* Do participants with PPA and study partners find treatment beneficial?\n* What patterns of treatment response are seen in participants?\n* Which outcome measures are most useful for evaluating changes in communication and quality of life?\n\nResearchers will compare participants who receive intervention immediately to participants assigned to a waitlist control group (who will receive treatment after a delay) to see whether participation in the treatment program is associated with improvements in communication and quality of life.\n\nParticipants will:\n\n* Take part in speech language therapy sessions delivered by video visit that combine restorative, compensatory, and partner-focused communication strategies. Treatment may take place after a waiting period.\n* Receive education and communication training together with their partner.\n* Complete speech, language, and cognitive assessments.\n* Complete questionnaires about communication abilities, daily functioning, and quality of life.",[67,68,69,70,71,72,73,74,75,76,27,77],"Primary Progressive Aphasia(PPA)","Semantic Dementia","Logopenic Progressive Aphasia (LPA)","Nonfluent Aphasia, Progressive","Progressive Aphasia","Semantic Variant Primary Progressive Aphasia (svPPA)","Semantic Aphasia","Logopenic Variant Primary Progressive Aphasia","Logopenic Variant of Primary Progressive Aphasia (LPA)","Logopenic Progressive Aphasia","Nonfluent Progressive Aphasia",[79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95],"speech-language pathology","neurodegenerative disease","logopenic","nonfluent","semantic","script training","teletherapy","remote","multimodal communication training","partner training","augmentative and alternative communication","AAC","Communication Book","bilingual","Spanish","Hispanic","Latino","2026-04-15",{"date":98,"type":44},"2026-04-21",{"date":100,"type":44},"2026-04-01",{"date":102,"type":21},"2027-08",{"name":104,"class":105},"Maya Henry","OTHER",1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":113,"sex":16,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":141},"100390419","artfl-lefftds-longitudinal-frontotemporal-lobar-degeneration-allftd-100390419","NCT04363684","ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)","Longitudinal Arm Inclusion Criteria\n\nFamilial FTLD (f-FTLD) participants (either is acceptable):\n\n* members of families in whom at least one member has a known disease-associated mutation in one of the major genes that cause f-FTLD: MAPT, GRN, C9orf72 (or other rare genes)\n* an autosomal dominant family history of a FTLD syndrome (without a known gene) verified by medical record review or well-documented family history including family members with a medical history consistent with FTLD or a related disorder.\n\nSporadic FTLD (s-FTLD) participants:\n\nSporadic participants should be symptomatic with no known family history nor a genetic mutation indicating f-FTLD. All sporadic participants must have an FTLD syndrome as a referring diagnosis; those determined by ALLFTD clinicians to have non-FTLD diagnoses will be excluded from longitudinal visits, but their baseline visit will be included in comparative datasets. For inclusion in the longitudinal follow-up, participants should meet research criteria for one of the following FTLD syndromes:\n\n* Progressive Supranuclear Palsy (PSP)\n* Semantic variant Primary Progressive Aphasia (svPPA)\n* Nonfluent variant Primary Progressive Aphasia (nfvPPA)\n* Corticobasal Degeneration (CBD)\u002FCorticobasal Syndrome (CBS)\n* Behavioral variant Frontotemporal dementia (bvFTD)\n* Frontotemporal Dementia with Amyotrophic Lateral Sclerosis (FTD\u002FALS)\n\nBiofluid-Focused Arm Inclusion Criteria\n\nParticipants enrolled in the biofluid arm may be either f-FTLD or s-FTLD. All general inclusion criteria apply. Participants should meet research criteria (as specified above) for any FTLD syndrome or meet familial FTLD inclusion criteria. Because the biofluid arm participants do not undergo the same detailed clinical and functional assessments required for the longitudinal arm, participants may be included regardless of primary language, as long as an appropriately translated consent is available.\n\nExclusion Criteria:\n\n* Known presence of a structural brain lesion (e.g. tumor, cortical infarct) that could reasonably explain symptoms in a symptomatic participant.\n* Known presence of an Alzheimer's disease causing mutation in PSEN1, PSEN2 or APP; or biomarker evidence for Alzheimer's disease as a cause of the clinical syndrome.\n* A previous history of Korsakoff encephalopathy, severe alcohol dependence (within 5 years of onset of dementia), frequent alcohol or other substance intoxication, or other neurological disorder.\n* Evidence through history or laboratory testing of uncorrected B12 deficiency (B12 \\\u003C 95% of local laboratory's normal value), unregulated hypothyroidism (TSH \\>150% of normal), HIV positive, renal failure (creatinine \\> 2), liver failure (ALT or AST \\> two times normal), respiratory failure that requires supplemental oxygen, large confluent white matter lesions, significant systemic medical illnesses such as deteriorating cardiovascular disease.\n* Current medication likely to affect CNS functions in the opinion of the site PI.\n* In the site investigator's opinion, the participant cannot complete sufficient key study procedures. The participant may be enrolled into the biofluid-focused arm if they can tolerate a blood draw and short clinical exam, but must be able to complete at least 75% of study procedures for enrollment into the longitudinal arm.",true,"18 Years",{"count":116,"type":21},2100,"OBSERVATIONAL","ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.",[120,121,122,123,72,27,124,125,126,127,128,129,130,131],"Frontotemporal Lobar Degeneration (FTLD)","Progressive Supranuclear Palsy (PSP)","Corticobasal Degeneration (CBD)","Behavioral Variant Frontotemporal Dementia (bvFTD)","FTD With Amyotrophic Lateral Sclerosis (FTD\u002FALS)","Amyotrophic Lateral Sclerosis","Oligosymptomatic PSP (oPSP)","C9orf72","GRN Related Frontotemporal Dementia","MAPT Gene Mutation","TBK1 Gene Mutation","Oligosymptomatic Progressive Supranuclear Palsy","2025-07-08",{"date":134,"type":44},"2025-07-11",{"date":136,"type":44},"2020-03-01",{"date":138,"type":21},"2026-06-30",{"name":140,"class":105},"Mayo Clinic",27]